936091-14-4 | TG 101209

Packsize	Purity	Availability	Price	Discounted Price
1mg	99%	in stock	$18.00	$13.00
5mg	99%	in stock	$36.00	$25.00
10mg	99%	in stock	$50.00	$35.00
25mg	99%	in stock	$83.00	$58.00
50mg	99%	in stock	$131.00	$92.00
100mg	99%	in stock	$217.00	$152.00

Description

• Catalog Number: AH85427
• Chemical Name: TG 101209
• CAS Number: 936091-14-4
• Molecular Formula: C26H35N7O2S
• Molecular Weight: 509.6668
• MDL Number: MFCD15528085
• SMILES: CN1CCN(CC1)c1ccc(cc1)Nc1ncc(c(n1)Nc1cccc(c1)S(=O)(=O)NC(C)(C)C)C

Computed Properties

• Complexity: 783
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 36
• Hydrogen Bond Acceptor Count: 9
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 8
• XLogP3: 4.2

Literature

• The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells.

  Experimental hematology 20120801

• Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20111201

• Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia.

  Leukemia 20110301

• TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells.

  American journal of hematology 20100901

• Prolactin-induced Jak2 phosphorylation of RUSH: a key element in Jak/RUSH signaling.

  Molecular and cellular endocrinology 20100830

• Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells.

  Blood 20091203

• TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.

  Leukemia 20070801